Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome
暂无分享,去创建一个
G. Parker | J. Waterton | R. Carano | A. Jackson | J. O'Connor | C. Rose | J. O’Connor
[1] Arvind P. Pathak,et al. Multiscale and multi-modality visualization of angiogenesis in a human breast cancer model , 2014, Angiogenesis.
[2] J R Griffiths,et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging , 2003, British Journal of Cancer.
[3] Geoff J M Parker,et al. Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging , 2009, Clinical Cancer Research.
[4] D. Collins,et al. Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity. , 2012, Radiology.
[5] Harry J de Koning,et al. Limited value of shape, margin and CT density in the discrimination between benign and malignant screen detected solid pulmonary nodules of the NELSON trial. , 2008, European journal of radiology.
[6] E. Rofstad,et al. Intratumor heterogeneity in blood perfusion in orthotopic human melanoma xenografts assessed by dynamic contrast‐enhanced magnetic resonance imaging , 2005, Journal of magnetic resonance imaging : JMRI.
[7] N. van Bruggen,et al. Quantification of viable tumor microvascular characteristics by multispectral analysis , 2008, Magnetic resonance in medicine.
[8] R. Coleman,et al. Recommendations on the Use of 18F-FDG PET in Oncology , 2008, Journal of Nuclear Medicine.
[9] R. Solé,et al. Metapopulation dynamics and spatial heterogeneity in cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[10] W. Niessen,et al. Quantification of Heterogeneity as a Biomarker in Tumor Imaging: A Systematic Review , 2014, PloS one.
[11] E. Rofstad,et al. Temporal heterogeneity in blood supply in human tumor xenografts. , 2008, Neoplasia.
[12] Susan M. Astley,et al. Classification of breast tissue by texture analysis , 1992, Image Vis. Comput..
[13] Functional principal component analyses of biomedical images as outcome measures , 2010 .
[14] M. Junttila,et al. Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.
[15] T. Powles,et al. Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer , 2011, Clinical Cancer Research.
[16] Robert M. Haralick,et al. Textural Features for Image Classification , 1973, IEEE Trans. Syst. Man Cybern..
[17] A. D. Van den Abbeele,et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. , 2007, AJR. American journal of roentgenology.
[18] M. Hatt,et al. Reproducibility of Tumor Uptake Heterogeneity Characterization Through Textural Feature Analysis in 18F-FDG PET , 2012, The Journal of Nuclear Medicine.
[19] Xiangyu Yang,et al. Quantifying Tumor Vascular Heterogeneity with Dynamic Contrast-Enhanced Magnetic Resonance Imaging: A Review , 2011, Journal of biomedicine & biotechnology.
[20] S. Orel,et al. BI-RADS categorization as a predictor of malignancy. , 1999, Radiology.
[21] V. Goh,et al. Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival. , 2013, Radiology.
[22] D L Buckley,et al. Enhancing fraction measured using dynamic contrast-enhanced MRI predicts disease-free survival in patients with carcinoma of the cervix , 2009, British Journal of Cancer.
[23] Samuel H. Hawkins,et al. Reproducibility and Prognosis of Quantitative Features Extracted from CT Images. , 2014, Translational oncology.
[24] D. Appelbaum,et al. Interobserver variability among measurements of the maximum and mean standardized uptake values on 18F-FDG PET/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors , 2010, Acta radiologica.
[25] Timothy D Johnson,et al. Prospective Analysis of Parametric Response Map–Derived MRI Biomarkers: Identification of Early and Distinct Glioma Response Patterns Not Predicted by Standard Radiographic Assessment , 2011, Clinical Cancer Research.
[26] A. Ozonoff,et al. FDG PET/CT interobserver agreement in head and neck cancer: FDG and CT measurements of the primary tumor site , 2012, Nuclear medicine communications.
[27] D. Buckley,et al. Heterogeneity analysis of Gd-DTPA uptake: improvement in breast lesion differentiation. , 1999, Journal of computer assisted tomography.
[28] H. Peitgen,et al. Chaos and Fractals , 2004 .
[29] A. Bjørnerud,et al. Glioma grading by using histogram analysis of blood volume heterogeneity from MR-derived cerebral blood volume maps. , 2008, Radiology.
[30] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J. Brenton,et al. Evaluation of nonenhancing tumor fraction assessed by dynamic contrast-enhanced MRI subtraction as a predictor of decrease in tumor volume in response to chemoradiotherapy in advanced cervical cancer. , 2010, AJR. American journal of roentgenology.
[32] R. Gillies,et al. Quantitative imaging in cancer evolution and ecology. , 2013, Radiology.
[33] I. Ellis,et al. The positive predictive value of mammographic signs: a review of 425 non-palpable breast lesions. , 1996, Clinical radiology.
[34] Chieko Azuma,et al. Multispectral quantification of tissue types in a RIF‐1 tumor model with histological validation. Part I , 2007, Magnetic resonance in medicine.
[35] G. Heppner. Tumor heterogeneity. , 1984, Cancer research.
[36] R. Beroukhim,et al. Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.
[37] R. Buchert,et al. Gene Expression Patterns and Tumor Uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an Orthotopic Mouse Xenotransplantation Model of Pancreatic Cancer , 2008, Journal of Nuclear Medicine.
[38] Paul S Mischel,et al. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. , 2011, Neuro-oncology.
[39] V. Goh,et al. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. , 2011, Radiology.
[40] Michael V Knopp,et al. Microarray gene expression analysis of murine tumor heterogeneity defined by dynamic contrast-enhanced MRI. , 2002, Molecular imaging.
[41] Quantitative analysis of whole‐tumor Gd enhancement histograms predicts malignant transformation in low‐grade gliomas , 2007, Journal of magnetic resonance imaging : JMRI.
[42] Chong-Yung Chi,et al. Tissue-Specific Compartmental Analysis for Dynamic Contrast-Enhanced MR Imaging of Complex Tumors , 2011, IEEE Transactions on Medical Imaging.
[43] P. Noker,et al. Variability of tumor response to chemotherapy II. Contribution of tumor heterogeneity , 2004, Cancer Chemotherapy and Pharmacology.
[44] A. Padhani,et al. Multiparametric imaging of tumor response to therapy. , 2010, Radiology.
[45] R. L. Butterfield,et al. Multispectral analysis of magnetic resonance images. , 1985, Radiology.
[46] M. Giger,et al. Volumetric texture analysis of breast lesions on contrast‐enhanced magnetic resonance images , 2007, Magnetic resonance in medicine.
[47] J. Waterton,et al. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours , 2003, British Journal of Cancer.
[48] Carol Walker,et al. Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype , 2007, Journal of magnetic resonance imaging : JMRI.
[49] H. Fine,et al. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. , 2011, Neuro-oncology.
[50] Geoff J M Parker,et al. Indexed distribution analysis for improved significance testing of spatially heterogeneous parameter maps: Application to dynamic contrast‐enhanced MRI biomarkers , 2013, Magnetic resonance in medicine.
[51] Corbin E. Meacham,et al. Tumour heterogeneity and cancer cell plasticity , 2013, Nature.
[52] J. Marcus,et al. First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[53] Arnau Oliver,et al. A review of automatic mass detection and segmentation in mammographic images , 2010, Medical Image Anal..
[54] R. Arceci. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2012 .
[55] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[56] G Johnson,et al. Histogram analysis versus region of interest analysis of dynamic susceptibility contrast perfusion MR imaging data in the grading of cerebral gliomas. , 2007, AJNR. American journal of neuroradiology.
[57] A. Jackson,et al. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies , 2012, Nature Reviews Clinical Oncology.
[58] C. Swanton. Intratumor heterogeneity: evolution through space and time. , 2012, Cancer research.
[59] B. Frieden,et al. Adaptive therapy. , 2009, Cancer research.
[60] D. D. Maki,et al. Radiogenomic analysis of breast cancer using MRI: a preliminary study to define the landscape. , 2012, AJR. American journal of roentgenology.
[61] Li Lan,et al. Fractal analysis of mammographic parenchymal patterns in breast cancer risk assessment. , 2007, Academic radiology.
[62] P. Lambin,et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.
[63] Matthew S. Brown,et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. , 2009, Radiology.
[64] R. Jain,et al. Spatial heterogeneity in tumor perfusion measured with functional computed tomography at 0.05 microliter resolution. , 1994, Cancer research.
[65] F E Turkheimer,et al. Quantification of intra-tumour cell proliferation heterogeneity using imaging descriptors of 18F fluorothymidine-positron emission tomography , 2013, Physics in medicine and biology.
[66] N. van Bruggen,et al. Quantification of tumor tissue populations by multispectral analysis , 2004, Magnetic resonance in medicine.
[67] Vladimir Ponomarev,et al. Molecular Imaging of Temporal Dynamics and Spatial Heterogeneity of Hypoxia-Inducible Factor-1 Signal Transduction Activity in Tumors in Living Mice , 2004, Cancer Research.
[68] Albert Lai,et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study , 2012, Journal of Neuro-Oncology.
[69] John C Waterton,et al. Qualification of imaging biomarkers for oncology drug development. , 2012, European journal of cancer.
[70] R. Jain,et al. 2H-nuclear magnetic resonance imaging of tumor blood flow: spatial and temporal heterogeneity in a tissue-isolated mammary adenocarcinoma. , 1992, Cancer research.
[71] N. Just,et al. Improving tumour heterogeneity MRI assessment with histograms , 2014, British Journal of Cancer.
[72] Siqing Shan,et al. The pervasive presence of fluctuating oxygenation in tumors. , 2008, Cancer research.
[73] W J Niessen,et al. Heterogeneity in DCE-MRI parametric maps: a biomarker for treatment response? , 2011, Physics in medicine and biology.
[74] R. Cox,et al. Acute Effects of Bevacizumab on Glioblastoma Vascularity Assessed with DCE-MRI and Relation to Patient Survival , 2009 .
[75] P. Grigsby,et al. Intratumoral Metabolic Heterogeneity of Cervical Cancer , 2008, Clinical Cancer Research.
[76] C. Sotak,et al. Multispectral tissue characterization in a RIF‐1 tumor model: Monitoring the ADC and T2 responses to single‐dose radiotherapy. Part II , 2007, Magnetic resonance in medicine.
[77] Stefan Delorme,et al. Pharmacokinetic analysis of malignant pleural mesothelioma-initial results of tumor microcirculation and its correlation to microvessel density (CD-34). , 2008, Academic radiology.
[78] G Johnson,et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. , 1999, Radiology.
[79] A. Jackson,et al. Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. , 2008, The Lancet. Oncology.
[80] M. Dewhirst,et al. Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. , 2005, Cancer research.
[81] H. Shim,et al. Molecular portraits of intratumoral heterogeneity in human ovarian cancer. , 2011, Cancer letters.
[82] Bal Sanghera,et al. Reproducibility of 2D and 3D fractal analysis techniques for the assessment of spatial heterogeneity of regional blood flow in rectal cancer. , 2012, Radiology.
[83] Rakesh K. Jain,et al. Spatial Heterogeneity in Tumor Perfusion Measured with Functional Computed Tomography at 0.05 µl Resolution , 1994 .
[84] Scott Fields,et al. Mapping pathophysiological features of breast tumors by MRI at high spatial resolution , 1997, Nature Medicine.
[85] John O. Prior,et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] Isabelle Salmon,et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[87] Brandon Whitcher,et al. DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6 , 2011, British Journal of Cancer.
[88] Geoff J M Parker,et al. Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2007, Clinical Cancer Research.
[89] Brandon Whitcher,et al. Quantifying spatial heterogeneity in dynamic contrast‐enhanced MRI parameter maps , 2009, Magnetic resonance in medicine.